A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

Summary

This was a single-arm, open-label, multicenter, phase II study to evaluate the efficacy and safety of the ALK inhibitor XZP-3621 when used as single agent in patients with ALK-rearranged stage IIIB, IIIC or IV NSCLC previously treated with other ALK inhibitors or non-previously treated.

Timeline

Start

2022-09

Primary completion

2025-05-07

Completion

2025-07-01

Drugs

Indications